85
49
Growth Score
-3 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
1384526
CovX’s biotherapeutic platform is a technology that links therapeutic peptides to an antibody “scaffold”.
About the Company
Covx is a biotechnology company. It engages in the discovery and development of long-acting biological therapies called CovX-Bodies. Its products pipeline focuses on targets that inhibit tumor angiogenesis and modulate metabolic disorders. Their products pipeline includes CVX-045, a thrombospondin-1 mimetic CovX-Body; TSP-1, a negative regulator of
angiogenesis that acts as a therapeutic target in oncology; CVX-060, a selective angiopoietin-2 antagonist COVX-BODY; and CVX-096, a long-acting GLP-1 mimetic COVX-BODY.
Covx was founded by Carlos Barbas in 2002 and is headquartered in San Diego, California.
